[HTML][HTML] Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
J Tol, M Koopman, A Cats, CJ Rodenburg… - … England Journal of …, 2009 - Mass Medical Soc
Background Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial
growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic …
growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic …
Genome-wide cell-free DNA fragmentation in patients with cancer
…, CJA Punt, GR Vink, NCT van Grieken, M Koopman… - Nature, 2019 - nature.com
Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with
cancer 1 . However, characteristics of the origins and molecular features of cell-free DNA are …
cancer 1 . However, characteristics of the origins and molecular features of cell-free DNA are …
From tumour heterogeneity to advances in precision treatment of colorectal cancer
CJA Punt, M Koopman, L Vermeulen - Nature reviews Clinical oncology, 2017 - nature.com
In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident. Hence,
biomarkers need to be developed that enable the stratification of patients with CRC into …
biomarkers need to be developed that enable the stratification of patients with CRC into …
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled …
M Koopman, NF Antonini, J Douma, J Wals… - The Lancet, 2007 - thelancet.com
Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not
been defined. Our aim was to investigate whether combination treatment is better than …
been defined. Our aim was to investigate whether combination treatment is better than …
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
…, AFJ de Haan, CJA Punt, M Koopman - Clinical Cancer …, 2014 - AACR
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal …
…, AH Honkoop, L Mol, CJA Punt, M Koopman - The Lancet, 2015 - thelancet.com
Background The optimum duration of first-line treatment with chemotherapy in combination
with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 …
with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 …
Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases
LGM van der Geest, J Lam-Boer, M Koopman… - Clinical & experimental …, 2015 - Springer
The aim of this study was to determine trends in incidence, treatment and survival of colorectal
cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This …
cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This …
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from …
…, MT Seymour, L Saltz, CJA Punt, M Koopman… - The Lancet …, 2016 - thelancet.com
Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival
compared with patients with metastatic colorectal cancer without peritoneal involvement. …
compared with patients with metastatic colorectal cancer without peritoneal involvement. …
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label …
…, R Van Hilligersberg, M Koopman… - The lancet …, 2018 - thelancet.com
Background Both perioperative chemotherapy and postoperative chemoradiotherapy improve
survival in patients with resectable gastric cancer from Europe and North America. To our …
survival in patients with resectable gastric cancer from Europe and North America. To our …
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic …
…, ABP Van Kuilenburg, CJA Punt, M Koopman… - The Lancet …, 2015 - thelancet.com
Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …